U.S. markets open in 9 hours 22 minutes

BioMarin Pharmaceutical Inc. (BMRN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
77.50-0.41 (-0.53%)
At close: 4:00PM EDT
Full screen
Loading interactive chart...
  • SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMRN, BTU, CACC, TRQ INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
    GlobeNewswire

    SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS BMRN, BTU, CACC, TRQ INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

    NEW ORLEANS, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: BioMarin Pharmaceutical Inc. (BMRN) Class Period: 2/28/2020 - 8/18/2020 Lead Plaintiff Motion Deadline: November 24, 2020 SECURITIES FRAUD To learn more, visit https://www.ksfcounsel.com/cases/nasdaqgs-bmrn/Peabody Energy Corp. (BTU) Class Period: 4/3/2017 - 10/28/2019 Lead Plaintiff Motion Deadline: November 27, 2020 SECURITIES FRAUD To learn more, visit https://www.ksfcounsel.com/cases/nyse-btu/Credit Acceptance Corporation (CACC) Class Period: 11/1/2019 - 8/28/2020 Lead Plaintiff Motion Deadline: December 1, 2020 SECURITIES FRAUD To learn more, visit https://www.ksfcounsel.com/cases/nasdaqgs-cacc/Turquoise Hill Resources Ltd. (TRQ) Class Period: 7/17/2018 - 7/31/2019 Lead Plaintiff Motion Deadline: December 14, 2020 SECURITIES FRAUD To learn more, visit https://www.ksfcounsel.com/cases/nyse-trq/If you purchased shares of the above companies and would like to discuss your legal rights and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner, Lewis Kahn, toll-free at 1-877-515-1850, via email (Lewis.Kahn@KSFcounsel.com), or via the case links above.If you wish to serve as a Lead Plaintiff in the class action, you must petition the Court on or before the Lead Plaintiff Motion deadline.About KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.To learn more about KSF, you may visit www.ksfcounsel.com.Contact:Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner lewis.kahn@ksfcounsel.com 1-877-515-1850 1100 Poydras St., Suite 3200 New Orleans, LA 70163

  • BMRN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 24, 2020 in the Class Action Filed on Behalf of BioMarin Pharmaceutical Inc. Limited Shareholders
    Newsfile

    BMRN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 24, 2020 in the Class Action Filed on Behalf of BioMarin Pharmaceutical Inc. Limited Shareholders

    New York, New York--(Newsfile Corp. - October 21, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) alleging that the Company violated federal securities laws.Class Period: February 28, 2020 and August 18, 2020Lead Plaintiff Deadline: November 24, 2020Learn more about your recoverable losses in BMRN:http://www.kleinstocklaw.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?id=10368&from=5The filed complaint alleges that BioMarin Pharmaceutical Inc. made materially false and/or misleading statements ...

  • GlobeNewswire

    ROSEN, GLOBAL INVESTOR COUNSEL, Reminds BioMarin Pharmaceutical Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – BMRN

    NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between February 28, 2020 and August 18, 2020, inclusive (the “Class Period”), of the important November 24, 2020 lead plaintiff deadline in securities class action. The lawsuit seeks to recover damages for BioMarin investors under the federal securities laws. To join the BioMarin class action, go to http://www.rosenlegal.com/cases-register-1960.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (2) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (3) as a result, BioMarin’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 24, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1960.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.Contact Information:        Laurence Rosen, Esq.         Phillip Kim, Esq.         The Rosen Law Firm, P.A.         275 Madison Avenue, 40th Floor         New York, NY 10016         Tel: (212) 686-1060         Toll Free: (866) 767-3653         Fax: (212) 202-3827         lrosen@rosenlegal.com         pkim@rosenlegal.com         cases@rosenlegal.com         www.rosenlegal.com